Irinotecanhydrochlorid 3 H2o Vitane

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecanhydrochlorid 3 H2o Vitane, is a Topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed in the treatment of metastatic colorectal cancer, typically in combination with fluoropyrimidine-based chemotherapy regimens for adult patients.

GNH USA supplies Irinotecanhydrochlorid 3 H2o Vitane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan Hydrochloride is indicated for colorectal cancer therapies that target the topoisomerase I pathway. - Metastatic colorectal cancer (first‑line): used with fluorouracil and leucovorin to improve response rates and overall survival. - Metastatic colorectal cancer (second‑line): employed after disease progression on prior chemotherapy to provide additional disease control. - Colorectal cancer (adjuvant setting): administered as part of postoperative chemotherapy to reduce recurrence risk.

Irinotecan may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: often severe and may require intensive management. - Nausea: frequent during and after infusion. - Vomiting: may accompany nausea. - Alopecia: hair loss observed in many patients. - Fatigue: general tiredness and weakness.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, a medical emergency. - Colitis/ileitis: severe inflammation of the colon or ileum. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Severe electrolyte disturbances: hypokalemia or hyponatremia.

Prior to initiating therapy, several safety measures should be observed. - Monitor blood counts: perform complete blood count before each cycle to detect neutropenia. - Assess liver function: evaluate hepatic enzymes and bilirubin prior to dosing and during therapy. - Evaluate gastrointestinal status: screen for bowel obstruction or inflammatory bowel disease before treatment. - Adjust dose in hepatic impairment: reduce dose according to bilirubin levels and liver function tests. - Avoid in patients with known hypersensitivity: discontinue if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan may interact with other medicines, influencing its safety or effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase SN‑38 exposure, heightening toxicity. - UGT1A1 inhibitors (e.g., atazanavir): reduce SN‑38 clearance, raising risk of neutropenia and diarrhea. - Concurrent myelosuppressive chemotherapy: additive bone‑marrow suppression may be life‑threatening.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): lower SN‑38 levels, potentially reducing efficacy. - Antidiarrheal agents (e.g., loperamide) used for symptom control: may mask severity of irinotecan‑induced diarrhea. - Anticoagulants (e.g., warfarin): monitor coagulation parameters as irinotecan can affect platelet counts.